Understanding mechanisms of toxicity: Insights from drug discovery research

Toxicology and Applied Pharmacology

Volumn 227, Issue 2, 2008, Pages 163-178

  Houck, Keith A ^a   Kavlock, Robert J ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

High content screening; High throughput screening; In vitro toxicology; Mechanism of toxicity; Predictive toxicology; Systems toxicology

Indexed keywords

DRUG METABOLIZING ENZYME; ENDOCRINE DISRUPTOR; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PESTICIDE; PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR FKHRL1; WNT PROTEIN;

APOPTOSIS; BIOLOGY; BIOTRANSFORMATION; CELL PROLIFERATION; CHEMICAL ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG ACTIVITY; ESTROGEN BINDING; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; NONHUMAN; PREDICTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TOXICOLOGY;

ANIMALS; DATA INTERPRETATION, STATISTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; PHARMACOLOGY;

ANIMALIA; MAMMALIA;

EID: 39049168646     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.10.022     Document Type: Review

References (106)

1. Adams C.L., Kutsyy V., Coleman D.A., Cong G., Crompton A.M., Elias K.A., Oestreicher D.R., Trautman J.K., and Vaisberg E. Compound classification using image-based cellular phenotypes. Methods Enzymol. 414 (2006) 440-468
2. Anderson G.L., Cole R.D., and Williams P.L. Assessing behavioral toxicity with Caenorhabditis elegans. Environ. Toxicol. Chem. 23 (2004) 1235-1240
3. Austin C.P., Brady L.S., Inse lT.R., and Collins F.S. NIH molecular libraries initiative. Science 306 (2004) 1138-1139
4. Berg E.L., Kunkel E.J., Hytopoulos E., and Plavec I. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J. Pharmacol. Toxicol. Methods 53 (2006) 67-74
5. Bernauer U., Glatt H., Heinrich-Hirsh B., Liu Y., Muckel E., Vieth B., and Gundert-Remy U. Heterologous expression of mouse cytochrome P450 2e1 in V79 cells: construction and characterization of the cell line and comparison with V79 cell lines stably expressing rat P450 2E1 and human P450 2E1. ATLA 31 (2003) 21-30
6. Bertelsen M. Multiplex analysis of inflammatory signaling pathways using a high-content imaging system. Methods Enzymol. 414 (2006) 348-363
7. Bettoun D.J., Burris T.P., Houck K.A., Buck II D.W., Stayrook K.R., Khalifa B., Lu J., Chin W.W., and Nagpal S. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Mol. Endocrinol. 17 (2003) 2320-2328
8. Borchert K.M., Sells Galvin R.J., Hale L.V., Trask O.J., Nickischer D.R., and Houck K.A. Screening for activators of the wingless type/Frizzled pathway by automated fluorescent microscopy. Methods Enzymol. 414 (2006) 140-150
9. Bucher J.R. The National Toxicology Program rodent bioassay: designs, interpretations, and scientific contributions. Ann. N.Y. Acad. Sci. 982 (2002) 198-207
10. Burns C.G., Milan D.J., Grande E.J., Rottbauer W., MacRae C.A., and Fishman M.C. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat. Chem. Biol. 1 (2005) 263-264
11. Cheng C.S., Alderman D., Kwash J., Dessaint J., Patel R., Lescoe M.K., Kinrade M.B., and Yu W. A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev. Ind. Pharm. 28 (2002) 177-191
12. Chin J., Adams A.D., Bouffard A., Green A., Lacson R.G., Smith T., Fischer P.A., Menke J.G., Sparrow C.P., and Mitnaul L.J. Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors. Assay Drug Dev. Technol. 1 (2003) 777-787
13. Crespi C.L., and Stresser D.M. Fluorometric screening for metabolism-based drug-drug interactions. J. Pharmacol. Toxicol. Methods 44 (2000) 325-331
14. Crespi C.L., Miller V.P., and Penman B.W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248 (1997) 188-190
15. Cui X., Thomas A., Han Y., Palamanda J., Montgomery D., White R.E., Morrison R.A., and Cheng K.C. Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo. J. Pharmacol. Toxicol. Methods 53 (2005) 215-218
16. De Rosa C.T., Nickle R., Faroon O., and Jones D.E. The impact of toxicology on public health policy and service: an update. Toxicol. Ind. Health 19 (2003) 115-124
17. Dix D.J., Houck K.A., Martin M.T., Richard A.M., Setzer R.W., and Kavlock R.J. The ToxCast Program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95 (2007) 5-12
18. Ennever F.K., and Lave L.B. Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. Regul. Toxicol. Pharmacol. 38 (2003) 52-57 (Aug)
19. Fairn G.D., Macdonald K., and McMaster C.R. A chemogenomic screen in Saccharomyces cerevisiae uncovers a primary role for the mitochondria in farnesol toxicity and its regulation by the Pkc1 pathway. J. Biol. Chem. 282 (2007) 4868-4874
20. Faucette S.R., Sueyoshi T., Smith C.M., Negishi M., Lecluyse E.L., and Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317 (2006) 1200-1209
21. Fennell M., Chan H., and Wood A. Multiparameter measurement of caspase 3 activation and apoptotic cell death in NT2 neuronal precursor cells using high-content analysis. J. Biomol. Screen. 11 (2006) 296-302
22. Fermini B., and Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2 (2003) 439-447
23. Finlayson K., Turnbull L., January C.T., Sharkey J., and Kelly J.S. [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur. J. Pharmacol. 430 (2001) 147-148
24. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., Sun J.H., Link J.R., Abbaszade I., Hollis J.M., Largent B.L., Hartig P.R., Hollis G.F., Meunier P.C., Robichaud A.J., and Robertson D.W. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57 (2000) 75-81
25. Fliri A.F., Loging W.T., Thadeio P.F., and Volkmann R.A. Biological spectra analysis: linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 261-266
26. Fliri A.F., Loging W.T., Thadeio P.F., and Volkmann R.A. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol. 1 (2005) 389-397
27. Fluckiger-Isler S., Baumeister M., Braun K., Gervais V., Hasler-Nguyen N., Reimann R., Van Gompel J., Wunderlich H.G., and Engelhardt G. Assessment of the performance of the Ames II assay: a collaborative study with 19 coded compounds. Mutat. Res. 558 (2004) 181-197
28. Frame L.T., Ozawa S., Nowell S.A., Chou H.C., DeLongchamp R.R., Doerge D.R., Lang N.P., and Kadlubar F.F. A simple colorimetric assay for phenotyping the major human thermostable phenol sulfotransferase (SULT1A1) using platelet cytosols. Drug Metab. Dispos. 28 (2000) 1063-1068
29. Gasparri F., Mariani M., Sola F., and Galvani A. Quantification of the proliferation index of human dermal fibroblast cultures with the ArrayScan high-content screening reader. J. Biomol. Screen. 9 (2004) 232-2343
30. Gasparri F., Cappella P., and Galvani A. Multiparametric cell cycle analysis by automated microscopy. J. Biomol. Screen. 11 (2006) 586-598
31. Gee P., Maron D.M., and Ames B.N. Detection and classification of mutagens: a set of base-specific Salmonella tester strains. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 11606-11610
32. Giaever G., Chu A.M., Ni L., Connelly C., Riles L., Veronneau S., Dow S., Lucau-Danila A., Anderson K., Andre B., Arkin A.P., Astromoff A., El-Bakkoury M., Bangham R., Benito R., Brachat S., Campanaro S., Curtiss M., Davis K., Deutschbauer A., Entian K.D., Flaherty P., Foury F., Garfinkel D.J., Gerstein M., Gotte D., Guldener U., Hegemann J.H., Hempel S., Herman Z., Jaramillo D.F., Kelly D.E., Kelly S.L., Kotter P., LaBonte D., Lamb D.C., Lan N., Liang H., Liao H., Liu L., Luo C., Lussier M., Mao R., Menard P., Ooi S.L., Revuelta J.L., Roberts C.J., Rose M., Ross-Macdonald P., Scherens B., Schimmack G., Shafer B., Shoemaker D.D., Sookhai-Mahadeo S., Storms R.K., Strathern J.N., Valle G., Voet M., Volckaert G., Wang C.Y., Ward T.R., Wilhelmy J., Winzeler E.A., Yang Y., Yen G., Youngman E., Yu K., Bussey H., Boeke J.D., Snyder M., Philippsen P., Davis R.W., and Johnston M. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418 (2002) 387-391
33. Giddings S.J., Clarke S.E., and Gibson G.G. CYP4A1 gene transfection studies and the peroxisome proliferator-activated receptor: development of a high-throughput assay to detect peroxisome proliferators. Eur. J. Drug Metab. Pharmacokinet. 22 (1997) 315-319
34. Giuliano K.A., DeBiasio R.L., Dunlay R.T., Gough A., Volosky J.M., Zock J., Pavlakis G.N., and Taylor D.L. High-content screening: a new approach to easing key bottlenecks in the drug discovery process. J. Biomol. Screen. 2 (1997) 249-259
35. Glover C.J., Rabow A.A., Isgor Y.G., Shoemaker R.H., and Covell D.G. Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem. Pharmacol. 73 (2007) 331-340
36. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 1-17
37. Handschin C., and Meyer U.A. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55 (2003) 649-673
38. Haendel M.A., Tilton F., Bailey G.S., and Tanguay R.L. Developmental toxicity of the dithiocarbamate pesticide sodium metam in zebrafish. Toxicol. Sci. 81 (2004) 390-400
39. Hastwell P.W., Chai L.L., Roberts K.J., Webster T.W., Harvey J.S., Rees R.W., and Walmsley R.M. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat. Res. 607 (2006) 160-175
40. Houck K.A., Borchert K.M., Hepler C.D., Thomas J.S., Bramlett K.S., Michael L.F., and Burris T.P. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 83 (2004) 184-187
41. Hutchinson T.H., Brown R., Brugger K.E., Campbell P.M., Holt M., Lange R., McCahon P., Tattersfield L.J., and van Egmond R. Ecological risk assessment of endocrine disruptors. Environ. Health Perspect. 108 (2000) 1007-1014
42. Kafert-Kasting S., Alexandrova K., Barthold M., Laube B., Friedrich G., Arseniev L., and Hengstler J.G. Enzyme induction in cryopreserved human hepatocyte cultures. Toxicology 220 (2006) 117-125
43. Kamath R.S., and Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods 30 (2003) 313-321
44. Kavlock R.J., Daston G.P., DeRosa C., Fenner-Crisp P., Gray L.E., Kaattari S., Lucier G., Luster M., Mac M.J., Maczka C., Miller R., Moore J., Rolland R., Scott G., Sheehan D.M., Sinks T., and Tilson H.A. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ. Health Perspect. 104 Suppl 4 (1996) 715-740
45. Kirkland D., Aardema M., Henderson L., and Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584 (2005) 1-256
46. Kirstein S.L., Atienza J.M., Xi B., Zhu J., Yu N., Wang X., Xu X., and Abassi Y.A. Live cell quality control and utility of real-time cell electronic sensing for assay development. Assay Drug Dev. Technol. 4 (2006) 545-553
47. Lang P., Yeow K., Nichols A., and Scheer A. Cellular imaging in drug discovery. Nat. Rev. Drug Discov. 5 (2006) 343-356
48. Lau Y.Y., Sapidou E., Cui X., White R.E., and Cheng K.C. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab. Dispos. 30 (2002) 1446-1454
49. Laws S.C., Yavanhxay S., Cooper R.L., and Eldridge J.C. Nature of the binding interaction for 50 structurally diverse chemicals with rat estrogen receptors. Toxicol. Sci. 94 (2006) 46-56
50. Lee M.Y., Park C.B., Dordick J.S., and Clark D.S. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 983-987
51. Lee P.J., Hung P.J., Rao V.M., and Lee L.P. Nanoliter scale microbioreactor array for quantitative cell biology. Biotechnol. Bioeng. 94 (2006) 5-14
52. Lee F.Y., Lee H., Hubbert M.L., Edwards P.A., and Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31 (2006) 572-580
53. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., and Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102 (1998) 1016-1023
54. Li A.P., Bode C., and Sakai Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem. Biol. Interact. 150 (2004) 129-136
55. Liao V.H., and Yu C.W. Caenorhabditis elegans gcs-1 confers resistance to arsenic-induced oxidative stress. BioMetals 18 (2005) 519-528
56. Lin J.H. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm. Res. 23 (2006) 1089-1116
57. Lindblom T., Pierce G., and Sluder A. A C. elegans orphan nuclear receptor contributes to xenobiotic resistance. Curr. Biol. 11 (2001) 864-868
58. Liu J., Knappenberger K.S., Kack H., Andersson G., Nilsson E., Dartsch C., and Scott C.W. A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. Mol. Endocrinol. 17 (2003) 346-355
59. Luo G., Cunningham M., Kim S., Burn T., Lin J., Sinz M., Hamilton G., Rizzo C., Jolley S., Gilbert D., Downey A., Mudra D., Graham R., Carroll K., Xie J., Madan A., Parkinson A., Christ D., Selling B., LeCluyse E., and Gan L.S. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30 (2002) 795-804
60. Luo G., Guenthner T., Gan L.S., and Humphreys W.G. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr. Drug Metab. 5 (2004) 483-505
61. MacDonald M.L., Lamerdin J., Owens S., Keon B.H., Bilter G.K., Shang Z., Huang Z., Yu H., Dias J., Minami T., Michnick S.W., and Westwick J.K. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2 (2006) 329-337
62. Mao B., Gozalbes R., Barbosa F., Migeon J., Merrick S., Kamm K., Wong E., Costales C., Shi W., Wu C., and Froloff N. QSAR modeling of in vitro inhibition of cytochrome P450 3A4. J. Chem. Inf. Model 46 (2006) 2125-2134
63. Mayer T., Jagla B., Wyler M.R., Kelly P.D., Aulner N., Beard M., Barger G., Tobben U., Smith D.H., Branden L., and Rothman J.E. Cell-based assays using primary endothelial cells to study multiple steps in inflammation. Methods Enzymol. 414 (2006) 266-283
64. Miller J.E., Vlasakova K., Glaab W.E., and Skopek T.R. A low volume, high-throughput forward mutation assay in Salmonella typhimurium based on fluorouracil resistance. Mutat. Res. 578 (2005) 210-224
65. Mizell M., and Romig E.S. The aquatic vertebrate embryo as a sentinel for toxins: zebrafish embryo dechorionation and perivitelline space microinjection. Int. J. Dev. Biol. 41 (1997) 411-423
66. Moore J.T., and Kliewer S.A. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153 (2000) 1-10
67. Murphy S.M., Palmer M., Poole M.F., Padegimas L., Hunady K., Danzig J., Gill S., Gill R., Ting A., Sherf B., Brunden K., and Stricker-Krongrad A. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods 54 (2005) 42-55
68. Nasevicius A., and Ekker S.C. The zebrafish as a novel system for functional genomics and therapeutic development applications. Curr. Opin. Mol. Ther. 3 (2001) 224-228
69. National Research Council, Committee on Toxicity Testing and Assessment of Environmental Agents. Toxicity Testing for Assessment of Environmental Agents: Interim Report (2006), The National Academies Press
70. National Research Council. Toxicity Testing in the Twenty-first Century: A Vision and Strategy (2007). http://dels.nas.edu/dels/reportDetail.php?Flink_id=4286&session_id= Prepublication edition available at: http://dels.nas.edu/dels/reportDetail.php?Flink_id=4286&session_id=
71. Nichols J.S., Parks D.J., Consler T.G., and Blanchard S.G. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain. Anal. Biochem. 257 (1998) 112-119
72. O'brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., and Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80 9 (2006) 580-604 (Sep)
73. Ozers M.S., Ervin K.M., Steffen C.L., Fronczak J.A., Lebakken C.S., Carnahan K.A., Lowery R.G., and Burke T.J. Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization. Mol. Endocrinol. 19 (2005) 25-34
74. Paolini G.V., Shapland R.H., van Hoorn W.P., Mason J.S., and Hopkins A.L. Global mapping of pharmacological space. Nat. Biotechnol. 24 (2006) 805-815
75. Parng C., Roy N.M., Ton C., Lin Y., and McGrath P. Neurotoxicity assessment using zebrafish. J. Pharmacol. Toxicol. Methods 55 (2007) 103-112
76. Parsons A.B., Lopez A., Givoni I.E., Williams D.E., Gray C.A., Porter J., Chua G., Sopko R., Brost R.L., Ho C.H., Wang J., Ketela T., Brenner C., Brill J.A., Fernandez G.E., Lorenz T.C., Payne G.S., Ishihara S., Ohya Y., Andrews B., Hughes T.R., Frey B.J., Graham T.R., Andersen R.J., and Boone C. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126 (2006) 611-625
77. Pulak R. Techniques for analysis, sorting, and dispensing of C. elegans on the COPAS flow-sorting system. Methods Mol. Biol. 351 (2006) 275-286
78. Phillips G.W., Irwin W.A., Howard-Cofield E.J., Randle L.E., Abraham V.C., Haskins J.R., and O'Brien P.J. Incorporation of an oxidative stress biomarker into high content screening (HCS) for human toxicity potential. 11th Annual Meeting of the Society for Biomol. Screen. (SBS), P05020 (2005)
79. Rausch O. High content cellular screening. Curr. Opin. Chem. Biol. 10 (2006) 316-320
80. Richards G.R., Smith A.J., Parry F., Platts A., Chan G.K., Leveridge M., Kerby J.E., and Simpson P.B. A morphology- and kinetics-based cascade for human neural cell high content screening. Assay Drug Dev. Technol. 4 (2006) 143-152
81. Roberts R.A., Ganey P.E., Ju C., Kamendulis L.M., Rusyn I., and Klaunig J.E. Role of the kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol. Sci. 96 (2007) 2-15
82. Rouleau N., Turcotte S., Mondou M.H., Roby P., and Bosse R. Development of a versatile platform for nuclear receptor screening using AlphaScreen. J. Biomol. Screen. 8 (2003) 191-197
83. Roymans D., Annaert P., Van Houdt J., Weygers A., Noukens J., Sensenhauser C., Silva J., Van Looveren C., Hendrickx J., Mannens G., and Meuldermans W. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab. Dispos. 33 (2005) 1004-1016
84. Sanguinetti M.C., and Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 440 (2006) 463-469
85. Sartipy P., Bjorquist P., Strehl R., and Hyllner J. Pluripotent human stem cells as novel tools in drug discovery and toxicity testing. IDrugs 9 (2006) 702-705
86. Schade R., Andersohn F., Suissa S., Haverkamp W., and Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356 (2007) 29-38
87. Shibata Y., Takahashi H., Chiba M., and Ishii Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab. Dispos. 30 (2002) 892-896
88. Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab. Pharmacokinet. 21 (2006) 257-276
89. Shoemaker R.H., Scudiero D.A., Melillo G., Currens M.J., Monks A.P., Rabow A.A., Covell D.G., and Sausville E.A. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr. Top. Med. Chem. 2 (2002) 229-246
90. Solly K., Wang X., Xu X., Strulovici B., and Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev. Technol. 2 (2004) 363-372
91. Sorota S., Zhang X.S., Margulis M., Tucker K., and Priestley T. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug. Dev. Technol. 3 (2005) 47-57
92. Trubetskoy O.V., and Shaw P.M. A fluorescent assay amenable to measuring production of d-glucuronides produced from recombinant UDP-glycosyl transferase enzymes. Drug Metab. Dispos. 27 (1999) 555-557
93. Trubetskoy O.V., Gibson J.R., and Marks B.D. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J. Biomol. Screen. 10 (2005) 56-66
94. Van der Jagt K., Munn S., Torslov J., and de Bruijn J. Alternative approaches can reduce the use of test animals under REACH. Report to the Directorate General JRC, Institute for Health and Consumer Protection, European Commission (2004). http://ihcp.jrc.ec.europa.eu/docs/ecb/Reducing_the_use_of_test_animals_u nder_REACH_IHCP_report.pdf (http://ihcp.jrc.ec.europa.eu/docs/ecb/Reducing_the_use_of_test_animals_ under_REACH_IHCP_report.pdf)
95. Viravaidya K., Sin A., and Shuler M.L. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol. Prog. 20 (2004) 316-323
96. Walsky R.L., and Obach R.S. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 32 (2004) 647-660
97. Walum E., Hedander J., and Garberg P. Research perspectives for pre-screening alternatives to animal experimentation On the relevance of cytotoxicity measurements, barrier passage determinations and high throughput screening in vitro to select potentially hazardous compounds in large sets of chemicals. Toxicol. Appl. Pharmacol. 207 2 Suppl (2005) 393-397
98. Waring R.H., and Harris R.M. Endocrine disrupters: a human risk?. Mol. Cell. Endocrinol. 244 (2005) 2-9
99. Weir S.W., and Weston A.H. The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels. Br. J. Pharmacol. 88 (1986) 121-128
100. Whitebread S., Hamon J., Bojanic D., and Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10 (2005) 1421-1433
101. Xing J.Z., Zhu L., Jackson J.A., Gabos S., Sun X.J., Wang X.B., and Xu X. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem. Res. Toxicol. 18 (2005) 154-161
102. Xing J.Z., Zhu L., Gabos S., and Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol. In Vitro 20 (2006) 995-1004
103. Yoshitomi S., Ikemoto K., Takahashi J., Miki H., Namba M., and Asahi S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol. In Vitro 15 (2001) 245-256
104. Yueh M.F., Kawahara M., and Raucy J. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol. In Vitro 19 (2005) 275-287
105. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
106. Zhang C., Willett C., and Fremgen T. Zebrafish: an animal model for toxicological studies. Curr. Protoc. Toxicol., Suppl. 17 (2003) 1-18